Mirati Therapeutics soars on report of Sanofi takeover interest
Panama7/iStock Editorial via Getty Images
Mirati Therapeutics (NASDAQ:MRTX) jumped almost 45% amid a report that Sanofi (NASDAQ:SNY) is exploring a possible acquisition. 
Sanofi (SNY) has been studying a possible purchase of Mirati (MRTX), according to a Bloomberg report on Thursday, which cited familiar people familiar with the matter.
Deliberations are ongoing, and it's not certain a deal will be reached, Bloomberg said. Mirati (MRTX) has a market cap of $2.9 billion.
A spokesperson for Mirati (MRTX) told Bloomberg the company doesn't comment on market rumors or speculation. A representative for Sanofi (SNY) also said it doesnât comment on market rumors.
The latest potential takeover comes after Bloomberg reported last November that Mirati (MRTX) was drawing interest from large pharmaceutical companies ahead of updates on its drug pipeline. The company has received interested in previous years without a deal coming to fruition. 
Mirati (MRTX) shares were already rising Thursday before the takeover report amid an FDA advisory panel meeting intended to discuss the risk/benefit profile of a rival product to Miratiâs lung cancer drug Krazati.
The FDA panel is slated to meet Thursday to discuss whether data submitted for Amgenâs (AMGN) lung cancer drug Lumakras is sufficient to support full approval. The drug was granted accelerated approval in 2021 and Amgen planned to use a confirmatory study called CodeBreaK to support its application for full approval.

More on Mirati Therapeutics

Mirati: Expansion Of Adagrasib With sNDA And Combination Studies
Mirati Therapeutics, Inc. 2023 Q2 - Results - Earnings Call Presentation
Mirati Therapeutics, Inc. (MRTX) Q2 2023 Earnings Call Transcript
Mirati stock up 9% amid FDA meeting on rival Amgen drug (update)
Jones Research sees Amgen FDA issues reading through to Mirati